Skip to main content
main-content

05.07.2018 | Original Paper

Platelet lysate promotes re-epithelialization of persistent epithelial defects: a pilot study

Zeitschrift:
International Ophthalmology
Autoren:
Mohammed A. Abu-Ameerh, Hanan D. Jafar, Maram H. Hasan, Muawyah D. Al Bdour, Mohammed Msallam, Osama H. Ababneh, Dana M. Alhattab, Ban Al-Kurdi, Abdelhalim A. Awidi, Abdalla S. Awidi

Abstract

Purpose

To study the use of autologous platelet lysate prepared in a standardized method for the healing of persistent corneal epithelial defects (PED).

Study design

Clinical and experimental investigation.

Methods

In this prospective pilot study (ClinicalTrials.gov identifier NCT02979912), ten patients with a PED duration of a minimum 14 days were included. Autologous platelet lysate was prepared in a standardized methodology. Repeated freeze–thaw cycles were used to lyse the platelets. Patients were advised to apply the eye drops four times a day and were evaluated at baseline and on days 7, 14, 21, 28.

Results

No adverse events were reported due to the use of undiluted autologous platelet lysate. A total of 70% of patients had complete re-epithelialization within 28 days. Of these, 40% healed within 14 days (effective group) and 30% within 28 days (partially effective group).

Conclusions

Undiluted autologous platelet lysate, prepared according to a standardized methodology, is a safe and effective adjunct therapy for the treatment of PED.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Premium-Inhalten der Fachzeitschriften, inklusive eines Print-Abos.

Literatur
Über diesen Artikel

Neu im Fachgebiet Augenheilkunde

15.06.2018 | Video plus | Ausgabe 7/2018

Diakaustische Kammerwinkeluntersuchung

Videobeitrag

01.06.2018 | themenschwerpunkt | Ausgabe 3/2018

Das Kind in der Kunst

22.05.2018 | Das Frühgeborene | Leitthema | Ausgabe 6/2018

Frühgeborenenretinopathie in welchem Stadium wie behandeln?

Aktueller Wissensstand und Ausblick